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Abstract To facilitate the wider application of the NADPH-
dependent P450BM3, we fused the monooxygenase with a
phosphite dehydrogenase (PTDH). The result ing
monooxygenase-dehydrogenase fusion enzyme acts as a
self-sufficient bifunctional catalyst, accepting phosphite as a
cheap electron donor for the regeneration of NADPH.
The well-expressed fusion enzyme was purified and ana-
lyzed in comparison to the parent enzymes. Using lauric acid
as substrate for P450BM3, it was found that the fusion enzyme
had similar substrate affinity and hydroxylation selectivity
while it displayed a significantly higher activity than the
non-fused monooxygenase. Phosphite-driven conversions of
lauric acid at restricted NADPH concentrations confirmed
multiple turnovers of the cofactor. Interestingly, both the fu-
sion enzyme and the native P450BM3 displayed enzyme con-
centration dependent activity and the fused enzyme reached
optimal activity at a lower enzyme concentration. This sug-
gests that the fusion enzyme has an improved tendency to
form functional oligomers.
To explore the constructed phosphite-driven P450BM3 as a
biocatalyst, conversions of the drug compounds omeprazole
and rosiglitazone were performed. PTDH-P450BM3 driven by
phosphite was found to be more efficient in terms of total
turnover when compared with P450BM3 driven by NADPH.
The results suggest that PTDH-P450BM3 is an attractive sys-
tem for use in biocatalytic and drug metabolism studies.
Keywords Drugmetabolites .Enzymecatalysis .Fattyacids .
NADPH regeneration . Oxidation . Protein engineering
Introduction
Cytochrome P450 monooxygenases (P450s) are versatile en-
zymes that catalyze a broad range of hydroxylation, epoxida-
tion, sulfoxidation, deamination, and dehalogenation reac-
tions and are attractive for applied biocatalysis (Sono et al.
1996; Bernhardt 2006). In vivo, the main functions include
steroid hydroxylation, fatty acid hydroxylation, and xenobiot-
ic detoxification, which consequently makes P450s of interest
to the pharmaceutical industry (Gillam and Hayes 2013;
Munro et al. 2013). Similar to other monooxygenases, catal-
ysis requires a suitable substrate, dioxygen, and two electrons
to be fed into the catalytic reaction cycle (Meunier et al. 2004).
The electrons are transferred to the heme from a reducing
cofactor via electron transfer proteins, which may be domains
fused to the monooxygenase component or may occur as sep-
arate proteins transferring electrons in transient assemblies
(Hannemann et al. 2007). The need for auxiliary redox pro-
teins presents an obstacle for the efficient application of P450s
because (a) complex cofactors have to be integrated into dif-
ferent proteins or protein domains to obtain a functional cata-
lyst and (b) participating enzymes need to match each other in
terms of concentration, stability, affinity, and activity to
achieve maximal turnover. In addition, the dependency on
NAD(P)H, slow electron transport, and coupling efficiency
can limit activity (Lundemo and Woodley 2015).
Electronic supplementary material The online version of this article
(doi:10.1007/s00253-016-7993-7) contains supplementary material,
which is available to authorized users.
* Marco W. Fraaije
m.w.fraaije@rug.nl
1 Department of Biochemistry, Groningen Biomolecular Sciences and
Biotechnology Institute, University of Groningen, Nijenborgh 4,
9747 AG Groningen, The Netherlands
2 Cardiovascular and Metabolic Diseases, Innovative Medicines and
Early Development Biotech Unit, AstraZeneca, Pepparedsleden 1,
Mölndal 43183, Sweden
Appl Microbiol Biotechnol
DOI 10.1007/s00253-016-7993-7
The highly active bacterial flavocytochrome P450BM3
(CYP102A1 from Bacillus megaterium, EC 1.14.14.1) natu-
rally circumvents some of these limitations. As a single poly-
peptide P450 (class VIII), it has an FAD- and FMN-containing
NADPH-cytochrome P450 reductase (BMR domain) fused to
the C-terminus of the P450 domain in a 119 kDa protein, that
is active as a dimer (Ruettinger et al. 1989; Neeli et al. 2005).
The enzyme can be solubly expressed in good yields in heter-
ologous hosts such as Escherichia coli. It is one of the few
P450s with reported activities above 1 s−1, which is partly due
to rapid electron transfer through the BMR domain (Munro
et al. 1996; Munro et al. 2002). The enzyme efficiently hy-
droxylates medium- to long-chain fatty acids. Arachidonic
acid was reported to be converted with the highest activity
(285 s−1). Low uncoupling rates of approx. 3.8% were deter-
mined when using laurate as substrate (Noble et al. 1999).
After it was shown that the substrate spectrum could be mod-
ulated by various mutations, P450BM3 was widely used as a
surrogate for class II mammalian P450s. It also is used as a
model P450 in mechanistic studies because of easy expres-
sion, high activity, and the availability of crystal structures of
the separate domains. Whitehouse et al. reviewed recent prog-
ress on this enzyme and describe numerous mutants accepting
non-natural substrates; many of them are bulky molecules like
drugs and related compounds (Whitehouse et al. 2012).
The regeneration of NADPH, which is stoichiometrically
consumed in the monooxygenation reaction, remains a major
challenge for the application of P450s. Several regeneration
approaches have been investigated, of which the enzymatic
regeneration of the cofactor is most commonly applied. One
possibility is the use of dehydrogenases; popular examples
being glucose-6-phosphate dehydrogenase (Ahmed et al.
1999; Falck et al. 2001; Volz et al. 2002; Murataliev et al.
2004; Chen et al . 2008), glucose dehydrogenase
(Sulistyaningdyah et al. 2005; Schewe et al. 2008; Schewe
et al. 2009), isocitrate dehydrogenase (Capdevila et al. 1996;
Schwaneberg et al. 2001; Peters et al. 2003; Landwehr et al.
2006), and formate dehydrogenase (Maurer et al. 2003;
Kühnel et al. 2007). Phosphite dehydrogenase (PTDH, EC
1.20.1.1) is one of the most cost efficient options; it regener-
ates NADPH while oxidizing cheap phosphite to phosphate
with the simultaneous reduction of NADP+. The large change
in energy of this reaction makes it thermodynamically almost
irreversible and only one inhibitor (sulfite) has been described
to date (Costas et al. 2001; Woodyer et al. 2003; Relyea and
van der Donk 2005).
The recycling of NADPHwith phosphite has been reported
for fusions of PTDH with several Baeyer-Villiger
monooxygenases (BVMOs) (Torres Pazmiño et al. 2009). A
codon-optimized gene was used for expression of PTDH-
BVMO fusions in E. coli. The employed PTDH contained
18 mutations which led to enhanced activity towards
NADP+, soluble expression, and stability (Johannes et al.
2007). Watanabe et al. also reported a fusion of PTDH to a
Pdx-PCNA2 construct which functioned as the BPCNA-uti-
lized protein complex of P450cam and its two electron
transfer-related proteins^ (PUPPET) for the regeneration of
NADH (Watanabe et al. 2013).
To facilitate the application of P450BM3 as a practical bio-
catalyst, we present here a fusion of P450BM3 to the optimized
variant of PTDH for cofactor recycling: PTDH-P450BM3. The
turnover of NADP+ to NADPH by the fused PTDH domain
should enable the use of phosphite as a cheap reductant for
performing P450BM3-catalyzed oxygenations with phosphate
as a byproduct (Scheme 1). The fusion protein is compared to
the regeneration systemwith the free PTDH and P450BM3 and
the P450BM3 without cofactor regeneration system.
Materials and methods
Materials
Unless stated otherwise, all chemicals and enzymes were ob-
tained from Sigma-Aldrich (Zwijndrecht, The Netherlands),
Oriental Yeast Co. (Tokyo, Japan), New England Biolabs
(Leiden, The Netherlands), and Agilent (Santa Clara, USA)
and used without further purification. Isopropyl-1-thio-β-D-
galactopyranoside (IPTG) was ordered at Iris Biotech GmBH
(Marktredwitz, Germany). Oligonucleotide primers were ob-
tained from Sigma Genosys. DNA sequencing was performed
at GATC Biotech AG (Konstanz, Germany).
Bacterial strains, plasmids, and cloning
E. coli TOP10 (Invitrogen, Carlsbad, CA, USA) was used for
genetic manipulations. For expression, a pBAD vector or a
modified pBAD vector with an NcoІ restriction site replacing
NdeІ were used. The plasmid pPTDH in which the codon-
optimized ptxD gene is fused to an N-terminal histidine tag
codes the 18-fold mutated PTDH without a fused
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Scheme 1 Schematic model of PTDH coupled to P450BM3 facilitating
phosphite-driven cofactor recycling
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monooxygenase. The vector pJOE-P450BM3 encoding the
wild-type gene cyp102A1 was a kind gift from Prof. B.
Hauer (University of Stuttgart) (Scheps et al. 2013). For the
creation of the fusion enzyme, the vector pCRE2-PAMO was
used as a template. It carries the 18-fold mutant of the phos-
phite dehydrogenase from Pseudomonas stutzeriWM88 with
N-terminal histidine tag and the pamO gene in fusion (Torres
Pazmiño et al. 2009). The fusion construct pCre2-P450BM3
was made implementing the In-Fusion technique from
Clontech, resulting in the sequence coding for the fusion con-
struct PTDH-P450BM3 (KX768143). Using primers with
overhangs matching the expression vector, cyp102A1
encoding P450BM3 was amplified via PCR using pJOE-
P450BM3 as template and then hybridized with the respective
expression vector, following the recommendations of the
manufacturer. For comparison studies with the unfused en-
zyme, cyp102A1 was subcloned into pBAD. Implementing
primers with an overhang matching the target vector,
cyp102A1 was amplified via a PCR reaction. The PCR prod-
uct was purified and utilized as a primer for a second PCR
reaction, subcloning the gene encoding P450BM3 into the re-
spective expression vector, yielding pBAD-P450BM3.
Screen for soluble enzyme expression
E. coli TOP10, BL21 (DE3), C43 (DE3) and SHuffle cells
harboring pCre2-P450BM3 were pre-grown overnight at
37 °C in ampicillin-supplemented LB medium (5 mL;
50 μg/mL). TB-medium (50 mL, ampicillin-supplemented)
in a non-baffled glass shaking flask (250 mL) was inoculated
with an OD600 of 0.08 and incubated at 37 °C and 180 rpm.
After an OD600 of 0.75–0.85 was reached, expression of
PTDH-P450BM3 was induced by the addition of 0.02% arab-
inose (final concentration). The cells were incubated for 25 h
at 30 °C and 135 rpm. Cells were harvested by centrifugation
(20 min, 8800×g, 4 °C), washed with ice-cold sodium phos-
phate buffer (50 mM, pH 7.5) and frozen (−20 °C) until cell
lysis by sonication. The cell debris was separated by centrifu-
gation and the content of PTDH-P450BM3 in the cell-free ex-
tract was investigated via CO-difference spectroscopy. For the
optimization of the arabinose concentration and the tempera-
ture for enzyme expression, TB-medium (2.5 mL) in 24-
square deep well plates with the sandwich cover system from
enzyscreen®, was inoculated with a preculture of E. coli
TOP10, harboring pCre2-P450BM3 (5 μL). Cultures were
grown at 17 °C (48 h), 24 °C (32 h), 30 °C (16 h), and
37 °C (16 h) and expression was induced directly after inoc-
ulation with 0% (as control), 0.002%, 0.02%, and 0.2% of
final arabinose. Cells were harvested via centrifugation and
cell pellets were frozen (−20 °C, 16 h). Cell lysis was per-
formed enzymatically (200μL lysis buffer consisting of 2 mg/
mL lysozyme, 0.1 mg/mL DNasel, 5 mM MgSO4 in 50 mM
Tris/HCl (pH 8)) and with a freeze-and-thaw cycle (plate was
shock frozen in liquid nitrogen and incubated in a shaker at
30 °C for 1 h). Samples were taken and the cell debris was
separated from the soluble fraction by centrifugation. Both the
lyzed cell and the soluble fraction were analyzed for expres-
sion of PTDH-P450BM3 via SDS-PAGE.
Enzyme expression
E. coli TOP10 cells harboring pBAD vectors encoding the
respective P450BM3 variants were pre-grown overnight
(37 °C) in 5 mL ampicillin-supplemented LB medium
(50 mg/mL). Four hundred milliliters of TB-medium
(ampicillin-supplemented) in non-baffled glass shaking flask
(2 L) were inoculated with an OD600 of 0.08 and incubated at
37 °C and 180 rpm. Expression was induced at an OD600 of
0.7–0.8 with arabinose (0.02%w/v) and 5-aminolevulinic acid
was added (0.5 mM). After induction, the cells were incubated
(17 °C, 180 rpm) over 44 h, harvested via centrifugation,
washed once with ice-cold sodium phosphate buffer
(50 mM, pH 7.5), and were stored until further use (−20 °C).
The PTDH was expressed as described before by Dudek
et al. (Dudek et al. 2013). E. coli TOP10 cells were trans-
formed with the plasmid and grown overnight at 37 °C in
5 mL of LB supplemented with ampicillin (50 μg/mL). The
next day cells were diluted (1:100) in TB supplemented with
ampicillin (50 μg/mL) and arabinose (0.02% w/v) and incu-
bated for 16 h at 30 °C. Cells were harvested via centrifuga-
tion, washed once with ice-cold sodium phosphate buffer
(50 mM, pH 7.5), and were stored until further use (−20 °C).
Enzyme purification
For purification, the frozen cells were resuspended in sodium
phosphate buffer (50 mM, pH 7.5, optionally supplemented
with DNase) at RT and disrupted via sonication on ice. The
resulting crude extract was centrifuged and the supernatant/
cell-free extract (CFE) diluted to a protein concentration of
∼20 mg/mL. The diluted CFE was then precipitated at an
ammonium sulfate (AS) concentration of 55% (w/v) and col-
lected by centrifugation (18,600×g, 15 min, 4 °C). The
resulting pellet was resuspended in sodium phosphate buffer
(50 mM, 500 mM NaCl pH 7.5) and subjected to an affinity
chromatography purification on a 5 mL HF HisTrap column
on an Äkta purifier (GE Healthcare). Fractionated elution was
carried out with imidazole (250 mM). The buffer was re-
moved by a second AS precipitation with 65% AS. The
resulting pellet was resuspended in ice-cold Tris/HCl. After
the addition of sucrose (20 mg/mL) for stabilization during
storage, the enzyme was shock frozen in liquid nitrogen and
stored at −80 °C (van Beek et al. 2015).
The PTDH was purified using Ni Sepharose High
Performance (GE Healthcare) as described before (Dudek
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et al. 2013). Ten percent glycerol (v/v) was added to the puri-
fied enzyme, which was shock frozen and stored at −20 °C.
Concentration determination
Concentrations of P450BM3 and PTDH-P450BM3 were deter-
mined by measuring CO-difference spectra (Omura and Sato
1964). After the addition of sodium dithionite (spatula tip), the
enzyme solution was incubated (5 min) and a baseline spec-
trum from 400 to 500 nm was recorded. The samples were
then bubbled with carbon monoxide (∼60 s) and incubated for
10 min before the UV spectrum from 400 to 500 nm was
recorded. After subtraction of the baseline spectrum, the
amount of P450 was calculated based on the maximum absor-
bance at 450 nm minus the absorption at 490 nm
(ε450nm = 91 mM
−1 cm−1). This method is specific for the
native P450-domain, therefore the concentration of native
fused PTDH is an estimation that might vary slightly from
the actual concentration.
The concentration of unfused PTDH was determined using
Waddell’s method (Waddell 1956) and the estimated extinc-
tion coefficient at 280 nm (ε280 nm = 26.5 mM
−1 cm−1).
Activity determination and kinetic measurements
NADPH oxidation or NADP+ reduction rates were measured
spectrophotometrically at 30 °C by following the absorption at
340 nm over 2–5 min (ε340 = 6.2 × 10
3 M−1 cm−1) in a final
volume of 500 μL in a quartz cuvette. For the investigation of
the properties of the P450BM3 (fused or WT), typical reaction
mixtures contained lauric acid as a substrate (2.5 mM from a
25 mM stock in ethanol/methanol (1:1)) and enzyme
(100 nM) in Tris buffer (50 mM, pH 7.5). The reaction was
started by the addition of NADPH (250 μM). For the investi-
gation of the PTDH, the reaction mixture contained enzyme
(100 nM) and phosphite as the substrate (5 mM). NADP+ was
added to start the reaction (250 μM). For the determination of
kinetic parameters or concentration-based activity, the con-
centration of the respective component was varied. All mea-
surements were performed in triplicate. Kinetic parameters
were calculated using the Michaelis-Menten equation as a
function of the respective substrate concentration in
GraphPad Prism 6.
Biotransformations in 96-well plate format
Purified enzyme (0.5 μM), substrate (10 μM), NADPH or
NADP+ (0.15 mM), and phosphite (1.5 mM) were mixed in
Tris/HCl buffer (50 mM, pH 7.5, 100 μL) in 96-well round-
bottomed plates. The reaction mixtures were incubated at
30 °C in a water bath or a plate shaker at 500 rpm. Samples
(50 μL) were taken and mixed with 100% acetonitrile
(100 μL). After centrifugation (4000 rpm, 20 min, 4 °C), the
resulting supernatant (50 μL) was transferred into 40% aceto-
nitrile in MilliQ water (150 μL) and stored at −20 °C prior to
analysis by UPLC-MS.
Biotransformations investigating cofactor recycling
Purified enzyme (1 μM), lauric acid (2.25 mM, 10% ethanol/
methanol as final concentration), NADPH (50 μM), and phos-
phite (4 mM) were mixed in Tris/HCl buffer (50 mM, pH 7.5)
in plastic falcon tubes (15 mL with 3 mL reaction mixture).
For the three different set-ups—PTDH-P450BM3, PTDH +
P450BM3, and P450BM3—reaction mixtures without enzyme
and without NADPH addition were the controls. The biotrans-
formations were incubated (30 °C, 180 rpm) and samples for
analysis in the molybdate assay and by GC-MS were taken in
triplicate per time point (20 and 120 μL).
Phosphate quantification via molybdate assay
Samples were taken from in vitro biotransformations to inves-
tigate cofactor recycling (20 μL). These were mixed with
molybdate reagent (200 μL; 100 mM zinc acetate, 10 mM
ammonium molybdate, and 0.1% SDS in MilliQ water, pH
5 (adjusted with HCl; stored in a PE bottle). Before an incu-
bation (30 min, 30 °C), ascorbic acid (50 μL of a 10% w/v
stock solution in MilliQ water, pH 5 (adjusted with NaOH))
was added. Measurements were performed in a Powerwave
96-well plate reader (Bio-TEK Instruments) at 850 and
700 nm. Phosphate standards containing potassium dihydroxy
phosphate (0.1–5 mM) were used to prepare the calibration
curve (Saheki et al. 1985; Dudek et al. 2013).
GC-MS analysis
Samples from biotransformations investigating cofactor
recycling (120 μL) were taken, and the conversions stopped
in Eppendorf tubes prepared with NaCl (6 mg) and H2SO4
(50%, 10 μL). The reaction mixtures were extracted twice
with twice the volume of MTBE/hexane (1:1); the internal
standard, decanoic acid (1 mM in the final derivatization mix-
ture) was added during the first extraction with the
MTBE/hexane phase. The organic phases were collected and
evaporated. Samples were resuspended in MTBE (60 μL),
followed by the addition of 1% TMS in BSTFA (60 μL) and
incubated at 75 °C for 30 min for derivatization. Tubes were
sealed with parafilm during derivatization (Lalman and
Bagley 2004; Scheps et al. 2013).
Measurements were performed on a HP-5 column ((5%
Phenyl) methylpolysiloxan, 30m × 0.25mm× 0.25μm), with
an injection volume of 1 μL at 300 °C (injection and interface
temperature) and helium as carrier gas. The method features a
temperature gradient from 40 to 300 °C (10 °C/min and
10 min isothermal at 300 °C) with a solvent cut-off of
Appl Microbiol Biotechnol
6 min, a split ratio of 30, and a flow of 1 mL min−1. The
detection limit was approximately 4 μM. 12-hydroxylauric
acid was used as a model product to estimate the response
factor for monohydroxylated lauric acids. Derivatized capric
acid, lauric acid, and 12-OH lauric acid elute after 10.6, 12.9,
and 16.6 min, respectively. The derivatized products were
identified via their fragmentation patterns. 11-hydroxylauric
acid (2), 10-hydroxylauric acid (3), and 9-hydroxylauric acid
(4) eluted at 18.5, 18.4, and 18.1 min, respectively.
UPLC-MS analysis
Samples were analyzed on a Waters ACQUITY UPLC liquid
chromatography system coupled to a Waters Synapt HDMS
mass spectrometer equipped with an electrospray (ESI)
ionization source. Samples taken during biotransforma-
tions were placed in a 96-well Nunc plate (injection vol-
ume 5–10 μL). Chromatograph separations were carried
out on an ACQUITY UPLC BEH C18 column (130 Å,
1.7 μm × 2.1 mm × 100 mm; Waters, Milford, MA, USA)
applying a flow rate of 0.5 mL min−1 at a column temperature
of 45 °C. The mobile phase consisted of ultra-pure water sup-
plemented with formic acid (0.1% v/v, phase A) and pure
acetonitrile (phase B). The gradient applied for separation
was 0.0–6.0 min (10–70% phase B), followed by a return to
the initial mobile phase composition over 0.01 min.
The MS analysis was performed under the following con-
ditions using the parameters stated. Positive electrospray ion-
ization (ESI) conditions in V-mode. A generic method with
two scan functions was used as follows: m/z 80–1000, cone
voltage 20 Vand 0.1 s scan time, the collision energy (CE) in
function 1 was 20 Vand in function 2 an energy ramp of 15–
45 V was applied, the transfer cell CE is 12 V. Data was
collected in centroid mode. Leucine-enkephalin was used as
lock mass (m/z 556.2771) for internal calibration at a concen-
tration of 250 pg mL−1 and a flow rate of 0.04 mL min−1. The
MS data was processed in MetaboLynx 4.1 (Waters, Milford,
MA, USA) using both the mass defect filter (MDF) and the
dealkylation tool. The list of proposed metabolites was
reviewedmanually. A semiquantitative estimation of substrate
conversion and metabolite formation were assessed by calcu-
lation of the fraction of the substrate peak area or a product
peak area to the total related peak area detected (Kulig et al.
2015).
Results
Enzyme expression and isolation
The plasmid pCre2-PAMO described by Torres Pazmiño et al.
was used as a template to create an expression plasmid for the
production of P450BM3 fused to the C-terminus of a codon-
optimized and stabilized PTDH which carries a His-tag at its
N-terminus (Torres Pazmiño et al. 2009). Using this construct,
six amino acids (SRSAAG) link the two proteins into one
fusion protein of 157 kDa. For producing the P450BM3 as a
reference for the non-fused enzyme, the P450BM3-encoding
gene was cloned into a regular pBAD vector, resulting in
expression of P450BM3 with a C-terminal His-tag (119 kDa)
(Fig. S1). The PTDHwas expressed from a pBAD vector with
an N-terminal His-tag (Dudek et al. 2013).
The expression of PTDH-P450BM3 was optimized in
terms of the type of E. coli host strain (Table S1), the
expression temperature, and the concentration of arabi-
nose added for induction (Fig. S2). Four E. coli strains
with different features for recombinant protein expression
were tested for soluble production of PTDH-P450BM3,
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Fig. 1 UV/Vis spectra of purified
P450BM3 (solid line, 4.5 μM) and
purified PTDH-P450BM3 (dashed
line, 2.6 μM)
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namely E. coli TOP10, E. coli BL21(DE3), E. coli C43,
and E. coli SHuffle. Expression of soluble and functional
enzyme was determined by CO-difference spectroscopy.
The most efficient strain for production of PTDH-
P450BM3 was E. coli TOP10, while almost no expression
was detected in E. coli BL21(DE3). To optimize soluble
expression in E. coli TOP10, the temperature and concen-
tration of inducer were varied; the best yield was obtained
at 17 °C and induction with 0.02–0.2% arabinose. As
judged by SDS-PAGE analysis, addition of δ-amino
levulinic acid further improved expression. Recombinant
production of PTDH-P450BM3 and P450BM3 using E. coli
TOP10 in a culture volume of 50 mL yielded 9.5 mg
PTDH-P450BM3 and 9.8 mg unfused P450BM3 in the
cell-free extract after 42 h cultivation. This shows that
the functional expression of both P450BM3 variants is very
efficient.
By exploiting the His-tag on both P450BM3 variants, both
enzymes could be easily purified. The integrity of the purified
P450BM3 and PTDH-P450BM3 was confirmed by the
characteristic UV/Vis-spectrum (Fig. 1). The UV/Vis-
spectral features of both proteins are nearly identical which
confirms the incorporation of the essential heme and flavin
cofactors.
To verify whether the obtained enzymes were functional,
monooxygenase and dehydrogenase activities were measured.
For testing P450BM3 activity, conversion of lauric acid (1) by
P450BM3 was analyzed. GC analysis revealed formation of
monohydroxylation products in positions 11 (2), 10 (3), and
9 (4) in similar amounts (Scheme 2). Bymonitoring the rate of
NADPH consumption using 50 nM enzyme, monooxygenase
activities of 6.7 s−1 for P450BM3 and 8.9 s
−1 for PTDH-
P450BM3 were found, while uncoupling rates (defined as
NADPH consumption in the absence of substrate) were deter-
mined as 0.22 s−1 for PTDH-P450BM3 and 0.19 s
−1 for
P450BM3. This shows that the fused enzyme displays a slightly
higher monooxygenase activity (Fig. 2a). For PTDH activity,
a similar trend was observed with a kobs of 0.71 s
−1 for the
non-fused PTDH and 2.5 s−1 for the fused PTDH (Fig. 2b).
These data show that PTDH-P450BM3 was fully functional,
displaying both monooxygenase and dehydrogenase
activities.
Enzyme concentration dependent activity
Neeli et al. demonstrated that inter-monomer electron transfer
is required for efficient hydroxylation of lauric acid and there-
fore the dimeric form of P450BM3 is the catalytically active
variant (Neeli et al. 2005). To examine if the oligomerization
behavior of the fused enzymes affected the reactivity of the
fusion construct, the specific activities of the two non-fused
enzymes and PTDH-P450BM3 were determined by following
the consumption or generation of NADPH at different enzyme
concentrations (1–50 nM for the P450 reaction, 1–100 nM for
the PTDH reaction). The observed monooxygenase activity
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Scheme 2 Model reaction catalyzed by P450BM3. NADPH is consumed
during the monohydroxylation of lauric acid (1) in position 11, 10 and 9
(2,3,4)
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Fig. 2 Enzyme concentration dependent activity of unfused P450BM3
(squares), unfused PTDH (squares), and PTDH-P450BM3 (circles). The
graphs show the relation between enzyme concentration and the initial
activities for a oxidation of 0.20 mMNADPH in the presence of 0.4 mM
lauric acid as substrate at varying concentrations of either P450BM3 or
PTDH-P450BM3 and b reduction of NADP
+ in the presence of 2.0 mM
phosphite as substrate at varying concentrations of either PTDH or
PTDH-P450BM3. Concentrations of (PTDH)-P450BM3 were determined
via CO-difference spectra, PTDH concentrations by Waddell’s method.
Experiments were performed in triplicate
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decreased sharply at enzyme concentrations below 10 nM.
Hyperbolic fitting of kobs values versus enzyme concentration
gave apparent half-saturation concentrations of 8.8 ± 2.1 and
3.3 ± 0.9 nM for P450BM3 and PTDH-P450BM3, respectively
(Fig. 2a). A similar enzyme concentration dependence was
previously reported for native P450BM3 and is assumed to
reflect the dissociation constant KD for the dimerization of
P450BM3, being active as a dimer (Neeli et al. 2005). The
lower KD for the fusion enzyme suggests that the fusion part-
ner promotes oligomerization.
The rate of phosphite-dependent NADP+ reduction by
PTDH (−P450BM3) was determined as a function of the con-
centration of the fused or non-fused PTDH (Fig. 2b). The kobs
for the PTDH reaction was relatively unaffected at enzyme
concentrations of 5–100 nM. However, at an enzyme concen-
tration of 1 nM, a decrease in the specific activity was ob-
served for PTDH-P450BM3, while an increase was detected
for the non-fused PTDH.
Kinetic parameters of PTDH-P450BM3
The steady state kinetic parameters of PTDH-P450BM3 were
determined and compared to those of the non-fused PTDH
and P450BM3. For analyzing the P450 kinetic parameters,
the lauric acid-dependent oxidation of NADPHwas measured
in the absence of phosphite for the fusion enzyme and for
P450BM3 (Table 1). The phosphite-dependent reduction of
NADP+ was measured for PTDH-P450BM3 and PTDH in
the absence of lauric acid (Table 2). The kinetic properties of
the fused enzyme were found to be in the same range as those
of the separate enzymes. While the Km values differed mar-
ginally, PTDH-P450BM3 displayed a higher kcat for both en-
zyme domains (for PTDH activity, 1.9 s−1 for PTDH vs.
2.3 s−1 for PTDH-P450BM3; for P450 activity, 7.3 s
−1 for
P450BM3 vs. 8.0 s
−1 for PTDH-P450BM3). These results con-
firm that the fused system is fully functional and that both
domains are at least as efficient as their non-fused counter-
parts. When considering lauric acid, the PTDH showed a low-
er activity than the P450BM3 component. Therefore, the
phosphite-dependent generation of NADPH should be the
rate-limiting step during bioconversions. Yet, for other
P450BM3 substrates, lower rates have been reported which
makes PTDH a suitable NADPH regeneration partner.
Phosphite-driven drug conversion under screening
conditions
The high catalytic activity makes P450BM3 an attractive bio-
catalyst for drug metabolism studies. Variants of the enzyme
can be used for the production of human metabolites (Reinen
et al. 2011). The application of PTDH- P450BM3 for exploring
drug metabolism under screening conditions was investigated
with omeprazole, a treatment for gastroesophageal reflux dis-
ease, and rosiglitazone, an antidiabetic drug. Both drugs are
metabolized by P450BM3 (Whitehouse et al. 2012).
To investigate the functionality of the PTDH-P450BM3 sys-
tem, conversion of both drugs was performed with NADPH or
with phosphite plus NADP+ as electron source. Furthermore,
conversion by the fusion enzyme was compared with conver-
sions catalyzed by P450BM3. For these conversions, 10 μM of
either omeprazole or rosiglitazone were incubated at 30 °C
with purified P450BM3 or PTDH-P450BM3 in a final reaction
volume of 100 μL. Samples were taken after 0 and 4 h and
analyzed by UPLC-MS.
Both enzyme variants produced a single metabolite when
using omeprazole (5) as substrate. A monohydroxylated
Table 1 Kinetics of NADPH dependent lauric acid oxidation. Kinetic parameters of PTDH-P450BM3 and P450BM3 for NADPH and lauric acid were
analyzed by following absorption of NADPH in a spectrophotometer at 340 nm. Specific activities were determined with 100 nM of the respective
enzyme and varying concentrations of either NADPH or lauric acid. When fixed, NADPH had a concentration of 200 μM and lauric acid of 2.5 mM
NADPH Lauric acid
kcat [s
−1] Km [μM] kcat/Km [s
−1 mM−1] kcat [s
−1] Km [μM] kcat/Km [s
−1 mM−1]
PTDH-P450BM3 6.9 ± 0.5 15.4 ± 2.3 448 8.0 ± 0.3 688 ± 78 11.6
P450BM3 6.0 ± 0.3 17.8 ± 2.7 337 7.3 ± 0.2 1427 ± 113 5.1
Table 2 Kinetics of phosphite-dependent cofactor regeneration. Kinetic parameters of PTDH-P450BM3 and PTDH for NADP
+ and phosphite were
analyzed by following absorption of NADPH in a spectrophotometer at 340 nm. Specific activities were determined with 100 nM of the respective
enzyme and varying concentrations of either NADP+ or phosphite. When fixed, NADP+ had a concentration of 200 μM and phosphite of 2 mM
NADP+ Phosphite
kcat [s
−1] Km [μM] kcat/Km [s
−1 mM−1] kcat [s
−1] Km [μM] kcat/Km [s
−1 mM−1]
PTDH-P450BM3 2.10 ± 0.02 9.5 ± 0.5 221 2.30 ± 0.01 148 ± 4 15.5
PTDH 1.78 ± 0.02 3.9 ± 0.2 452 1.87 ± 0.02 201 ± 10 9.3
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metabolite (6) was evident from a mass shift from the parent
compound of 15.996 Da. Hydroxylation of one of the methyl
groups of the 4-methoxy-3,5-dimethylpyridine moiety in
omeprazole was proposed on the basis of fragmentation data
(Scheme 3a). As expected, conversion with P450BM3 only
occurred when NADPH was added as an electron source
and not in reactions with phosphite and NADP+. Around
16% of the hydroxylated metabolite was formed in the
NADPH-driven P450BM3 reaction (Fig. 3a). In the NADPH-
driven reaction with the fusion enzyme, 25% of the same
metabolite was formed. Reactions driven on phosphite as the
sole electron donor showed similar behavior in terms of prod-
uct formation. Under the tested conditions, the bifunctional
enzyme was more efficient compared to non-fused P450BM3.
In reactions with rosiglitazone (MH+ 358.12; 7) two main
products were formed: a demethylated metabolite (MH+
344.11; 8) and anN-oxide (MH+ 374.12; 9) (Scheme 3b) were
proposed based on the fragmentation data. The unfused
P450BM3 produced these metabolites in reactions with
NADPH as electron donor with a yield of 26% for the demeth-
ylation and 36% for the N-oxidation product after 4 h. Very
little conversion (<5%) occurred when NADP+ and phosphite
were used. The ratio of demethylation vs. N-oxidation shifted
when using PTDH-P450BM3; around 50% demethylation and
15% N-oxidation product were formed in reactions with the
bifunctional enzyme (Fig. 3b). As observed for omeprazole,
the total turnover was higher in reactions with the fusion en-
zyme. Furthermore, conversions with PTDH-P450BM3 did not
show a significant difference when changing the electron
source (NADPH or phosphite).
Cofactor recycling
To establish the efficiency of the engineered PTDH-P450BM3
fusion enzyme with respect to cofactor recycling, conversions
were analyzed in greater detail. Omeprazole and rosiglitazone
are poorly soluble in aqueous solution and so lauric acid was
used as a model substrate to investigate bioconversions with
limited NADPH supply. Reactions were performed with the
fused enzyme (PTDH-P450BM3), the non-fused parent pro-
teins (PTDH + P450BM3), and P450BM3 without any cofactor
recycling enzyme. Reaction mixtures consisted of 2.25 mM
lauric acid, 4 mM phosphite, 50 μM NADPH, and 1.0 μM
enzyme. As a consequence, conversions of lauric acid greater
than 2.2% relied on cofactor regeneration by the PTDH.
Conversions were monitored over time by taking samples
for the analysis of phosphate production and the quantification
of lauric acid and its metabolites.
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Fig. 3 Conversions of a omeprazole and b rosiglitazone by P450BM3 and
PTDH-P450BM3. Substrate was used at concentrations of 10 mM in a
total volume of 100 mL. Reactions were carried out at 30 °C; reaction
progress was measured after 4 h in comparison to 0 h samples by UPLC-
MS. Phosphite-driven reactions contained phosphite and NADP+,
whereas NADPH-driven reactions contained NADPH and phosphite.
The yield of product and remaining substrate was determined as a
percentage of the respective peak area to the total related peak area.
React ions were performed in dupl icate (5 = omeprazole,
6 = monohydroxylated omeprazole, 7 = rosiglitazone, 8 = demethylated
rosiglitazone, 9 = monohydroxylated rosiglitazone)
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Uncoupling was investigated by comparing the amount of
phosphate formed, as an indicator of the amount of
NADPH regenerated, and the amount of lauric acid oxi-
dized. The concentration of phosphate was measured via a
blue reaction product formed with molybdate (Saheki
et al. 1985). Formation of phosphate which exceeded the
production of hydroxylated lauric acids indicated
uncoupling was occurring. Both the conversion of lauric
acid and the amount of products formed were quantified
after TMS derivatization by GC-MS analysis (Scheps
et al. 2013). Three monohydroxylation products of lauric
acid were identified via the characteristic elution and frag-
mentation patterns of their TMS derivatized products
(Fig. S3 and Fig. S4) and were formed at varying concen-
trations. The products were identified as 11-hydroxylauric
acid (2), 10-hydroxylauric acid (3), and 9-hydroxylauric
acid (4).
Conversions of lauric acid by PTDH-P450BM3 reached
completion after less than 2 h with a yield of 2.2 mM of
combined monohydroxylation products in a ratio of 32.8%
9-hydroxylauric acid (4), 30.7% 10-hydroxylauric acid (3),
and 36.7% 11-hydroxylauric acid (2). Excess phosphate, com-
pared to the total amount of hydroxylated products formed,
was produced mainly after conversion of lauric acid was com-
plete. After 4 h, 25% more phosphate than product was
formed, but during the first 1.5 h, only 10% phosphate pro-
duction was uncoupled from substrate hydroxylation and
uncoupling was still less earlier in the reaction (<5%). From
the amount of monohydroxylated products formed, it was
calculated back that phosphite supplied electrons for 44 turn-
overs of the NADPH cofactor. Even more turnovers of
NADPH occurred, if the uncoupling is taken into consider-
ation (Fig. 4a, b).
Conversions performed with non-fused PTDH and
P450BM3 were less efficient than with the fusion enzyme (pro-
duction of 1.6 mMmonohydroxylated lauric acid after 2.5 h in
comparison to 2.2 mM for the fusion enzyme). After 4 h,
1.86 mM of the combined hydroxylation products were
formed with a similar ration between 9-, 10-, and 11-
hydroxylauric acid as observed for the fused enzyme. The
reaction did not reach completion after 4 h. Thus, phosphate
production was still coupled to the product formation (approx.
6% uncoupling). In the time frame analyzed, at least 36 turn-
overs of the NADPH cofactor occurred (Fig. 4c, d).
The P450BM3 without cofactor regeneration system was not
able to drive the reaction to a product yield near the concentra-
tion of cofactor added (only 27.6 μM hydroxylated product
formed, with 1.94 mM of lauric acid remaining, when 50 μM
NADPH were supplied). With 30.0% 9-hydroxylauric acid (4),
25.6% 10-hydroxylauric acid (3), and 44.4% 11-hydroxylauric
acid (2), the latter was favored more than in the other two
reactions (Fig. 4e, f). As expected, no significant phosphate
was produced in reactions without PTDH (data not shown).
Interestingly, in controls without NADPH added to the re-
action, PTDH-P450BM3 and PTDH + P450BM3 still formed
small amounts of product (16.4 and 10.4 μM of total
monohydroxylated products), whereas no monohydroxylated
products were formed in the controls with P450BM3. Possibly,
these conversions are driven by phosphite and minor amounts
of NADPH and/or NADP+ co-purified with the enzyme.
Discussion
While the natural fusion of the P450 oxygenase domain to the
BMR domain in P450BM3 already makes this P450 a conve-
nient system for oxidative biocatalysis, a NADPH
regenerating system is still required for its efficient applica-
tion.With the design of PTDH-P450BM3, a fully self-sufficient
system for phosphite-driven conversion of substrates by
P450BM3 was engineered. It utilizes the reducing power of
phosphite to generate NADPH from NADP+, which then do-
nates electrons into the P450 reaction cycle for oxidation. This
simplifies enzyme handling by providing the benefits of a
single biocatalyst, without compromising the catalytic proper-
ties of either the PTDH or P450BM3.
Specific activity was fully retained at lower enzyme con-
centrations for PTDH-P450BM3 compared to P450BM3, indi-
cating a higher affinity for oligomerization. An increase in the
specific activity was observed for both enzymes in the fusion.
Fogle et al. postulated that product release is the rate-limiting
step for the variant stabilized and optimized for the conversion
of NADP+ (referred to as 12x-PTDH, lacking mutation
A176R compared to the variant fused to P450BM3) (Fogle
and van der Donk 2007). The C-terminal modification of the
PTDH might lead to structural changes that promote the re-
lease of NADPH from the active site. For the P450BM3, the
product release and the electron transfer from the BMR to the
heme domain are described as rate limiting (Whitehouse et al.
2012). Considering that the PTDH is N-terminally fused to the
heme domain of P450BM3, a structural change that influences
product release seems likely. Additionally, the assembly of the
BMR domain of one P450BM3 with the heme domain of a
second P450BM3 may be promoted by the fusion, and there-
fore the electron transfer may improve.
Phosphite-dependent conversion of omeprazole and
rosiglitazone as exemplary drugs by PTDH-P450BM3 showed
comparable turnover to NADPH-driven reactions. The total
turnover was slightly higher than with conversions containing
P450BM3 and NADPH in excess. This indicates that the fused
enzyme is more efficient despite the observation that PTDH
showed a lower activity than P450BM3 when testing the fused
domains separately. This can be explained by the relatively
low rate of turnover of these drugs by P450BM3. Butler et al.
reported conversion of omeprazole by wild-type P450BM3
implementing glucose-6-phosphate dehydrogenase as a
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cofactor recycling system. In reaction mixtures with purified
enzyme (0.1 μM) and the same concentration of substrate as
used here (10 μM), less than 1% product formation was ob-
served within 30 min. Higher conversions are described for
mutants in the heme domain of P450BM3 (e.g., F87 V ∼50%)
(Butler et al. 2013). In this study, we report a higher turnover
for the wild-type P450BM3 without any cofactor recycling sys-
tem (16%) and a slightly higher turnover for the fusion en-
zyme (25–26%). The higher yields are most likely caused by
the higher enzyme concentrations that we employed and a
prolonged reaction time. Clearly, it would be attractive to in-
corporate known mutations in P450BM3 in order to generate a
powerful phosphite-driven PTDH-P450BM3 capable of gener-
ating drug metabolites.
The p-hydroxylation of the pyridine ring and N-
demethylation of rosiglitazone are both major reactions when
considering the metabolism of these drugs in humans while
the N-oxidation is not listed as a relevant pathway (Cox et al.
2000). N-demethylation is mainly performed by the human
P450 2C8 (Baldwin et al. 1999). Rosiglitazone conversions
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Fig. 4 Conversions of lauric acid by different P450BM3 systems. All
reactions contained 2.25 mM lauric acid, 4.0 mM phosphite, and
50 μM NADPH, thus making any product formation above 0.05 mM
dependent on phosphite oxidation. a, b PTDH-P450BM3. c, d PTDH +
P450BM3. e, f P450BM3. Samples were taken and analyzed by GC-MS to
determine substrate depletion (a, c, and e; solid line) and product
formation (a, c, and f) (9-hydroxylauric acid, dotted line; 10-
hydroxylauric acid, dotted dashed line; 11-hydroxylauric acid, dashed
line). In b and d, uncoupling was examined by following phosphate
production measured with the molybdate assay (solid lines) and
comparing it to total product formation determined by GC-MS (double
dotted dashed line). For P450BM3 conversions, only a background of
phosphate was detected (data not shown). All samples were measured
in triplicate. Controls were reaction mixtures without enzyme and
reaction mixtures without NADPH
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of up to 99% by mutants of P450BM3 using glucose-6-
phosphate dehydrogenase for cofactor recycling have been
described by Reinen et al. 2011. In conversions by PTDH-
P450BM3, less than 3% of rosiglitazone was detected in reac-
tions after 4 h, suggesting that conversions by the fusion en-
zyme were comparably efficient. Integrating the mutations
described by Reinen et al. might increase the total turnover
slightly—ratios for demethylation and N-oxidation products
were not described. Interestingly, we observed that the ratio of
two formed metabolites from rosiglitazone depended on
which P450BM3-based biocatalyst was used; native P450BM3
favored N-oxidation, whereas the fusion enzyme showed a
strong preference for formation of one of the major human
metabolites, the demethylated product. The N-terminal region
of the unfused P450BM3 is described as one of the regions that
are involved in the switch of conformation between the open
and closed state (Ravichandran et al. 1993). We therefore as-
sume that a fusion to the N-terminus might induce minor
changes in the structure of the active site or the substrate
access channel that influence regioselectivity.
With lauric acid as a model compound for conversions at
higher substrate concentrations (2.25 mM), the fused enzyme
proved superior to the non-fused system. Using PTDH-
P450BM3, the conversion was complete within 2 h, while
using non-fused P450BM3, the reaction did not reach comple-
tion within 4 h. In both cases, the reaction was driven far
beyond the amount of NADPH added, while significant
uncoupling of phosphate production from the formation of
the monohydroxylated products only took place after the re-
a c t i o n h ad r e a ch ed comp l e t i o n . The r a t i o o f
monohydroxylation products of lauric acid was in agreement
with what was reported byMiura et al. for the NADPH-driven
conversion by wild-type P450BM3 (Miura and Fulco 1975).
Watanabe et al. investigated a fusion of PTDH to the
BPCNA-utilized protein complex of P450 and its two electron
transfer-related proteins^ (PUPPET) for the regeneration of
NADH in conversions by P450cam (Watanabe et al. 2013).
The PTDH-PUPPET fusion retained, similar to the PTDH-
P450BM3 fusion, kinetic parameters comparable to the parent
constructs, and the consumption of camphor was driven on
phosphite and NAD+. The rate of NAD+ reduction by PTDH
was lower than the rate of NADH oxidation by the P450, as
we report for the PTDH-P450BM3 system. In both cases, co-
factor reduction was assumed to be the rate-limiting step. In
biotransformations with 1 mM D-camphor, 20 μM NAD+,
and 10 mM phosphite, a turnover of the cofactor of 46 was
reached, while here more than 50 turnovers based on phos-
phate production in conversions of lauric acid are described.
Watanabe et al. achieved the same turnover in reactions with
the non-fused PTDH after 8 h reaction time, suggesting that
unfused PTDH and P450BM3 may reach the same turnover as
the fused system over an extended incubation. While
Watanabe et al. implement a NADH-dependent system, here
the recycling of the more expensive NADPH is investigated.
This demonstrates the capability of the PTDH to cooperate
with different electron donor systems of P450s. Coupling to
various P450s enhances the scope of substrate conversions
that can be driven on phosphite.
A limiting factor in the conversions reported by Watanabe
et al. was a loss of activity of the PTDH during incubations
with phosphite. The use of a stabilized version of the PTDH
for our studies might have prevented this effect for conver-
sions by PTDH-P450BM3. The main limiting factor was the
substrate solubility for rosiglitazone and omeprazole and sub-
strate and/or product inhibition in case of lauric acid. It is
expected that these bottlenecks can be overcome by enzyme
immobilization, as described for the PTDH-PUPPET fusion
and non-fused P450BM3 (Maurer et al. 2003; Weber et al.
2010; Lee et al. 2014; Tan et al. 2015).
Overall, these findings suggest that the designed fusion
enzyme PTDH-P450BM3 is an efficient bifunctional biocata-
lyst with potential application in drug metabolism studies and
for the production of fine chemicals.
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